A phase 1/2 study of FOG-001, a first-in-class direct β-catenin: TCF inhibitor, in patients with colorectal cancer (CRC) and other locally advanced or metastatic solid tumors.

Authors: Kyriakos P. Papadopoulos, Michael Cecchini, Moh'd M. Khushman, Meredith Pelster, Jordi Rodon Ahnert, Shivaani Kummar, Rona Yaeger, Sunil Sharma, Amber Wells, Amanda Garofalo, Lalith V Akella, Ziyang Yu, Marie Huong Nguyen, Keith W. Orford, Samuel J. Klempner

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps3169

Source: Full article

---

Abstract

TPS3169